

INTRODUCTION	XX
STUDY GOAL AND OBJECTIVES	XX
REASONS FOR DOING THIS STUDY	XX
INTENDED READERSHIP	XX
SCOPE OF REPORT	XXI
METHODOLOGY AND INFORMATION SOURCES.....	XXI
ANALYST'S CREDENTIALS.....	XXII
RELATED BCC REPORTS	XXII
BCC ONLINE SERVICES.....	XXII
DISCLAIMER	XXIII
 SUMMARY.....	 XXIV
MAJOR FINDINGS	XXIV
<i>SUMMARY TABLE U.S. BLOOD MARKET, THROUGH 2012</i> (\$ MILLIONS).....	 XXV
<i>SUMMARY FIGURE U.S. BLOOD MARKET, 2007 AND 2012</i> (\$ MILLIONS).....	 XXV
 OVERVIEW	 1
THE BLOOD INDUSTRY	1
MARKET STRUCTURE AND SIZE	2
<i>TABLE 1 U.S. BLOOD PRODUCTS AND COLLECTION AND</i> <i>PROCESSING PRODUCTS MARKET, THROUGH 2012</i> (\$ MILLIONS).....	 2
HISTORY OF THE BLOOD INDUSTRY	2
<i>TABLE 2 TIMELINE OF THE BLOOD INDUSTRY.....</i>	<i>3</i>
<i>TABLE 2 (CONTINUED).....</i>	<i>4</i>
BLOOD AND ITS COMPONENTS.....	5
PLASMA	5
<i>TABLE 3 COMPOSITION OF BLOOD.....</i>	<i>6</i>
CELLULAR ELEMENTS	6
Red and White Blood Cells.....	6
Platelets	7
IMMUNOGLOBULIN PRODUCTS	7
THE DANGERS OF TRANSFUSED BLOOD	8
TRANSFUSION ASSOCIATED RISKS.....	8
Diseases Contracted from Blood Transfusions and Related Identification Testing.....	 9
<i>TABLE 4 MAJOR DISEASES CONTRACTED FROM BLOOD</i> <i>TRANSFUSIONS</i>	 <i>9</i>
<i>TABLE 4 (CONTINUED).....</i>	<i>10</i>
HIV/AIDS.....	10
<i>TABLE 5 CBER-LICENSED HIV DONOR SCREENING TESTS</i>	<i>11</i>
<i>TABLE 5 (CONTINUED).....</i>	<i>12</i>

Hepatitis A	12
Hepatitis B	12
<i>TABLE 6 CBER-LICENSED SCREENING TESTS FOR HEPATITIS B</i>	<i>13</i>
Hepatitis C	14
<i>TABLE 7 CBER-LICENSED SCREENING TESTS FOR HEPATITIS C</i>	<i>14</i>
Hepatitis D	14
Hepatitis E	15
Human T Cell Lymphotropic Virus—(HTLV-I, -II).....	15
<i>TABLE 8 CBER-LICENSED SCREENING TESTS FOR HTLV-I AND</i> <i>HTLV-II</i>	<i>16</i>
Cytomegalovirus	16
<i>TABLE 9 CBER-LICENSED SCREENING TESTS FOR CMV</i>	<i>16</i>
<i>TABLE 9 (CONTINUED)</i>	<i>17</i>
<i>TABLE 10 CBER-LICENSED SCREENING TESTS FOR WEST NILE</i>	<i>18</i>
“Mad Cow Disease”—Creutzfeldt-Jakob Disease (CJD)	18
Syphilis.....	19
Chagas Disease	19
Chagas Disease (Continued)	20
Current Status of Blood Donor Screening for Chagas Disease.....	21
EFFORTS TO CREATE A VIRUS-FREE BLOOD SUPPLY	21
Plasma Treatments	22
Trinitrobutyl Phosphate and Sodium Cholate	22
Methylene Blue-treated Plasma.....	22
Amatosalen HCL—Treated Plasma.....	23
Platelet Treatments.....	23
RBCs.....	24
NEGATIVE REACTIONS FROM BLOOD TRANSFUSIONS.....	24
Negative Reactions from Blood ... (Continued).....	25
BLOOD/PLASMA COMPONENT RISKS	26
 THE BLOOD MANAGEMENT SYSTEM: BLOOD COLLECTION, PROCESSING, AND USE	 27
BLOOD COLLECTION	27
ORGANIZATIONS COLLECTING BLOOD	27
For-profit Blood Collection	27
Plasma Collection Centers.....	28
National Donor Deferral Registry	28
Nonprofit Blood Collection	28
American Red Cross.....	28
Community Blood Banks	29
Hospitals	29
Other Blood Collection Sites.....	29
BLOOD DONATION DEMOGRAPHICS.....	30

DONOR RECRUITMENT AND REGULATIONS.....	30
BLOOD SCREENING AND EVALUATION	30
METHODS FOR COLLECTING BLOOD FROM A DONOR	31
Manual Collection.....	31
Automated Collection	32
Plasmapheresis	32
Plateletpheresis	33
Leukopheresis	33
Red Blood Cell Apheresis	33
PLASMA COLLECTION	33
Commercial Nature of Plasmapheresis	34
Global Nature of the Plasma Industry	34
Plasma Fractionators	35
Distributors/Brokers.....	35
BLOOD TYPING AND TESTING FOR DISEASES.....	36
Blood Typing	36
<i>TABLE 11 TESTS ROUTINELY PERFORMED ON BLOOD</i>	
<i>DONATIONS</i>	36
<i>TABLE 11 (CONTINUED)</i>	37
<i>TABLE 12 BLOOD TYPE ANTIGEN/ANTIBODY REACTIONS</i>	37
Methods of Typing	37
Manual Blood Typing Methods	38
Slide/Tile Testing	38
Tube Testing.....	38
Microplate.....	38
Automated Blood Typing and Screening Methods	38
Blood Testing	39
Blood Storage	39
BLOOD PROCESSING.....	40
Preparation and Use of the Components.....	40
Red Blood Cell Components	40
Platelets.....	40
BLOOD TRANSFUSIONS.....	41
Testing before Transfusion.....	41
Manual Crossmatch Techniques	41
Major Crossmatch	41
Minor Crossmatch.....	41
Antibody Screen	42
Coombs Test	42
TYPES OF TRANSFUSIONS.....	42
Whole Blood	42
Packed Red Blood Cells	43
Platelets	44
Leukocytes	44

Fresh Frozen Plasma (FFP)	44
<i>TABLE 13 SELECTED USES OF FFP</i>	44
Cryoprecipitate	45
Coagulation Factors.....	45
<i>TABLE 14 LISTING OF BLOOD PRODUCTS FOR THERAPEUTIC USE</i>	46
Immune Serum Globulin/Intramuscular Immune Globulins (IMIG)/Intravenous Immune Globulin (IGIV)	46
Factor VIII	47
Factor IX and Factor IX Complex.....	47
Factor VIIa.....	47
Fibrin/Thrombin	48
Therapeutic Apheresis.....	48
BLOOD MANAGEMENT ISSUES	48
AVAILABILITY ISSUES	48
BLOODLESS SURGERY.....	49
SAFETY ISSUES—RISK MANAGEMENT.....	50
<i>TABLE 15 FACTORS TO REDUCE RISKS OF TRANSFUSION- ASSOCIATED DISEASES</i>	50
Better Donor Screening.....	50
Better Viral Screening Tests.....	51
Get More Repeat Donors	51
Develop Better Viral Inactivation Processes.....	51
Selective Use of Blood Derivative Products.....	51
REGULATION OF THE BLOOD BUSINESS	52
REGULATION OF THE U.S. BLOOD BUSINESS	52
<i>TABLE 16 FEDERAL ORGANIZATIONS RESPONSIBLE FOR U.S. BLOOD SAFETY</i>	52
<i>TABLE 16 (CONTINUED)</i>	53
STATUTORY AUTHORITY OF THE FDA.....	53
Center for Biologics Evaluation and Research.....	53
Office of Regulatory Affairs (ORA).....	54
Office of Biologics, the Division of Blood and Blood Products	54
<i>TABLE 17 FDA AUTHORITY IN REGULATING BLOOD BANKING AND BLOOD PRODUCTS</i>	55
THE MAJOR REGULATIONS AND POLICY MATTERS CONCERNING THE U.S.BLOOD SUPPLY	55
The Clinical Laboratory Improvement Act of 1988 (CLIA)	56
The FDA'S Five Layers	56
The FDA Blood Action Plan	57
<i>TABLE 18 MAIN BLOOD REGULATION ISSUES IDENTIFIED BY THE FDA</i>	57
<i>TABLE 18 (CONTINUED)</i>	58

Team Biologics	58
HOW REGULATIONS GET IMPLEMENTED	59
Inspecting Blood Banks and Plasma Collection Facilities.....	59
TABLE 19 14 MAJOR AREAS OF CONCERN FOR INSPECTING	
BLOOD FACILITIES.....	60
OTHER ORGANIZATIONS INVOLVED IN BLOOD	
REGULATION	61
National Heart, Lung, and Blood Institute (NHLBI)	61
Blood Diseases and Resources Program	61
Occupational Safety and Health Administration (OSHA).....	62
Health Care Financing Administration (HCFA).....	63
The Department of Defense	63
State Regulatory Agencies	63
VOLUNTARY REGULATION BY PROFESSIONAL AND	
TRADE ASSOCIATIONS	64
American Association of Blood Banks	64
American Blood Resources Association	65
America's Blood Centers (ABC)	65
PPTA: Plasma Products Therapeutics Association.....	66
THE EUROPEAN UNION (EU) BLOOD DIRECTIVE	66
International Society for Blood Transfusion (ISBT) 128	67
THE FUTURE OF BLOOD REGULATION	67
THE BLOOD AND BLOOD PRODUCTS MARKET	68
DRIVING FORCES OF THE INDUSTRY	68
FIGURE 1 VARIABLES INFLUENCING THE DYNAMICS OF DEMAND	
FOR BLOOD FOR TRANSFUSION.....	68
MARKET OVERVIEW	69
FIGURE 2 BLOOD MARKET COST AND PRICING ANALYSIS.....	70
BLOOD COLLECTION DATA	70
TABLE 20 U.S. BLOOD COLLECTION AND TRANSFUSION DATA,	
THROUGH 2012 (MILLION UNITS/PTS.)	71
FIGURE 3 U.S. BLOOD COLLECTION AND TRANSFUSION DATA,	
2005-2012 (MILLION UNITS/PTS.).....	71
TABLE 21 U.S. PLASMA COLLECTION DATA, THROUGH 2012	
(MILLION UNITS/L).....	72
FIGURE 4 U.S. PLASMA COLLECTION DATA, 2005-2012 (MILLION	
UNITS/L).....	73
CHANGING PATTERNS OF TRANSFUSION PROCEDURES	73
Leukoreduction	74
Impact of Autologous Donations	74
Types of Autologous Transfusions.....	75
Risks of PABD	76
PRICING OF BLOOD	76
TABLE 22 COST OF BLOOD COMPONENTS, THROUGH 2012 (\$).....	77

National Blood Exchange (NBE).....	78
RBCs and Leukoreduced RBCs.....	79
Platelets	79
Random Donor Platelets.....	80
Fresh Frozen Plasma (FFP)	80
Cryoprecipitate	80
Washed Cells.....	80
Deglycerolized Cells.....	81
Other Blood Components	81
Granulocytes	81
Gamma-Irradiated Blood.....	81
AVERAGE COST OF TRANSFUSION	81
<i>TABLE 23 AVERAGE COST OF TRANSFUSION TO PATIENT BY</i>	
<i>PRODUCT TYPE, 2007 (\$)</i>	82
PLASMA AND PLASMA-DERIVED PRODUCTS	82
Plasma Market Size.....	83
Plasma Therapeutic Products	83
<i>TABLE 24 U.S. MARKET SIZE PLASMA THERAPEUTIC</i>	
<i>DERIVATIVES BY TYPE, THROUGH 2012 (\$ MILLIONS)</i>	83
<i>FIGURE 5 SHARE OF PLASMA THERAPEUTIC DERIVATIVES BY</i>	
<i>TYPE, 2007 AND 2012 (%)</i>	84
Albumin and Plasma Protein Fraction (PPF).....	84
FDA Notification Regarding Safety of	
Albumin Administration in Critically Ill.....	85
Recombinant Human Albumin	85
Albumin Market Dynamics.....	86
<i>TABLE 25 CURRENTLY MARKETED ALBUMIN AND PLASMA</i>	
<i>PROTEIN FRACTION (PPF) PRODUCTS</i>	87
Albumin and PPF Market Size	87
<i>TABLE 26 U.S. MARKET FOR HUMAN SERUM ALBUMIN AND PPF,</i>	
<i>THROUGH 2012 (UNITS, PRICE, AND VALUE)</i>	88
Clotting Factors	89
<i>TABLE 27 BLOOD CLOTTING FACTORS</i>	89
Hemophilia	90
<i>TABLE 28 WORLDWIDE AND U.S. HEMOPHILIA STATISTICS, 2007</i>	90
Market Demand and Market Size	91
<i>TABLE 29 U.S. MARKET FOR PLASMA-DERIVED AND</i>	
<i>RECOMBINANT CLOTTING FACTORS, THROUGH 2012</i>	
<i>(\$ MILLIONS)</i>	91
<i>FIGURE 6 U.S. SHARE FOR PLASMA-DERIVED AND RECOMBINANT</i>	
<i>CLOTTING FACTORS, 2007 AND 2012 (%)</i>	92
Factor VIII.....	92
<i>TABLE 30 FDA-APPROVED FACTOR VIII PRODUCTS</i>	93
<i>TABLE 30 (CONTINUED)</i>	94

	Factor VIII (Continued).....	95
<i>TABLE 31</i>	<i>U.S. MARKET SHARE FACTOR VIII COMPANIES, 2007.....</i>	<i>96</i>
<i>FIGURE 7</i>	<i>MARKET SHARE OF FACTOR VIII COMPANIES, 2007 (%).....</i>	<i>96</i>
	Factor IX.....	96
<i>TABLE 32</i>	<i>FDA-APPROVED FACTOR IX PRODUCTS.....</i>	<i>97</i>
	Factor VIIa.....	97
	Other Factors	98
	Prothrombin Complex Concentrates.....	98
<i>TABLE 33</i>	<i>FDA-APPROVED PROTHROMBIN COMPLEX CONCENTRATE PRODUCTS.....</i>	<i>98</i>
	Fibrin Sealants and Thrombin	99
<i>TABLE 34</i>	<i>U.S. MARKET FOR FIBRIN/THROMBIN, THROUGH 2012 (\$ MILLIONS).....</i>	<i>99</i>
	Antithrombin III	99
<i>TABLE 35</i>	<i>U.S. MARKET FOR ANTITHROMBIN III—THROMBATE, THROUGH 2012 (\$ MILLIONS).....</i>	<i>100</i>
	Immunoglobulins	100
	IVIG.....	101
<i>TABLE 36</i>	<i>SELECTED CONDITIONS TREATED BY IVIG</i>	<i>101</i>
<i>TABLE 37</i>	<i>FDA-APPROVED IMMUNOGLOBULINS.....</i>	<i>102</i>
	Hyperimmunes.....	103
<i>TABLE 38</i>	<i>FDA-APPROVED HYPERIMMUNE IMMUNOGLOBULINS</i>	<i>103</i>
<i>TABLE 38 (CONTINUED)</i>		<i>104</i>
	Other	104
	IMIG.....	104
	Immunoglobulin Market Size.....	105
<i>TABLE 39</i>	<i>U.S. MARKET FOR IMMUNOGLOBULINS BY TYPE, THROUGH 2012 (\$ MILLIONS).....</i>	<i>105</i>
<i>FIGURE 8</i>	<i>U.S. MARKET FOR IMMUNOGLOBULINS BY TYPE, 2007 AND 2012 (\$ MILLIONS).....</i>	<i>106</i>
	RSV.....	106
	CMV Immunoglobulin	107
	Hepatitis B Immune Globulin	107
	RhoD Immunoglobulin	107
	Tetanus Immunoglobulin (TIG).....	108
	Rabies Immunoglobulin.....	108
	Varicella Immunoglobulin.....	108
	Vaccinia Immune Globulin Intravenous (VIG)	109
	Alpha-1-Proteinase Inhibitor	109
	Alpha-1-Proteinase (Continued).....	110
BLOOD TESTING AND TYPING MARKETS		111
	MARKET SIZE.....	111
<i>TABLE 40</i>	<i>VALUE U.S. BLOOD TYPING AND BLOOD SCREENING MARKET, THROUGH 2012 (\$ MILLIONS)</i>	<i>111</i>

<i>FIGURE 9 VALUE AND MARKET SHARE OF U.S. BLOOD TYPING AND BLOOD SCREENING MARKET, 2007 AND 2012 (%)</i>	112
TYPES OF TESTING	113
POLYMERASE CHAIN REACTION (PCR) AMPLIFICATION.....	113
<i>TABLE 41 CBER-LICENSED PCR SCREENING TESTS</i>	113
<i>TABLE 41 (CONTINUED)</i>	114
NUCLEIC ACID AMPLIFICATION TEST (NAT)	114
<i>TABLE 42 CBER-LICENSED NAT DONOR SCREENING TESTS</i>	114
IMMUNOASSAY	115
<i>TABLE 43 IMMUNOASSAY CBER-LICENSED SCREENING TESTS</i>	115
<i>TABLE 43 (CONTINUED)</i>	116
MARKET SIZE BLOOD TESTING PRODUCTS FOR DONOR SCREENING	117
<i>TABLE 44 AVERAGE COST OF DONOR BLOOD TESTING, 2007 AND 2012 (\$ MILLIONS)</i>	117
<i>TABLE 45 THE U.S. BLOOD DONOR SCREENING TESTING MARKET BY TYPE OF TESTS, THROUGH 2012 (\$ MILLIONS)</i>	117
<i>FIGURE 10 U.S. BLOOD DONOR SCREENING TESTING MARKET BY TYPE, 2007 AND 2012 (\$ MILLIONS)</i>	118
MARKET PARTICIPANTS DONOR SCREENING PRODUCTS	118
<i>TABLE 46 LIST OF SUPPLIERS DONOR SCREENING TESTS</i>	119
BLOOD TYPING.....	119
MARKET SIZE BLOOD TYPING	120
<i>TABLE 47 THE U.S. BLOOD TYPING MARKET—INSTRUMENTS AND SUPPLIES BY TYPE, THROUGH 2012 (\$ MILLIONS)</i>	120
MARKET STRUCTURE AND PARTICIPANTS	120
Manual Typing Methods	121
Automated Blood Typing.....	121
Immucor	121
Ortho.....	122
Olympus	123
BLOOD COLLECTION/TRANSFUSION PRODUCTS AND PROCESSING EQUIPMENT AND SUPPLIES	123
<i>TABLE 48 U.S. MARKET FOR BLOOD AND PLASMA COLLECTION/TRANSFUSION PRODUCTS, THROUGH 2012 (\$ MILLIONS)</i>	124
COLLECTION PRODUCTS	124
<i>TABLE 49 U.S. MARKET FOR COLLECTION PRODUCTS BY TYPE, THROUGH 2012 (\$ MILLIONS)</i>	125
PLASMA AND BLOOD COLLECTION EQUIPMENT	125
<i>TABLE 50 U.S. MARKET FOR BLOOD AND PLASMA COLLECTION EQUIPMENT BY TYPE, THROUGH 2012 (\$ MILLIONS)</i>	126
<i>FIGURE 11 SHARE OF U.S. MARKET FOR BLOOD AND PLASMA COLLECTION PRODUCTS BY TYPE, 2007 AND 2012 (%)</i>	126

Blood Salvage.....	127
OTHER COLLECTION EQUIPMENT	127
<i>TABLE 51 U.S. MARKET FOR OTHER PLASMA COLLECTION</i>	
<i>PRODUCTS, THROUGH 2012 (\$ MILLIONS)</i>	127
MARKET PARTICIPANTS	128
Haemonetics.....	128
PCS2	128
TCD Total Containment Unit	128
MCS+ 8150 System.....	128
Cell Saver System.....	129
OrthoPAT System.....	129
ACP 215 System.....	129
Baxter.....	129
Autopheresis-C.....	129
Alyx Component Collection System	130
CS-3000 Plus Blood Cell Separator.....	130
Amicus Separator.....	130
Gambro BCT	130
PLASMA COLLECTION SETS	131
<i>TABLE 52 U.S. MARKET FOR PLASMA COLLECTION SETS,</i>	
<i>THROUGH 2012 (\$ MILLIONS)</i>	131
BLOOD BAGS	131
<i>TABLE 53 U.S. MARKET FOR BLOOD BAGS, THROUGH 2012</i>	
<i>(\$ MILLIONS)</i>	132
TRANSFUSION PRODUCTS.....	132
<i>TABLE 54 U.S. MARKET FOR TRANSFUSION PRODUCTS BY TYPE,</i>	
<i>THROUGH 2012 (\$ MILLIONS)</i>	133
Transfusion Sets	133
<i>TABLE 55 U.S. MARKET FOR TRANSFUSION SETS, THROUGH 2012</i>	
<i>(\$ MILLIONS)</i>	133
Blood Filter Market	133
<i>TABLE 56 U.S. MARKET FOR FILTERS, THROUGH 2012</i>	
<i>(\$ MILLIONS)</i>	134
Accessories	134
<i>TABLE 57 U.S. MARKET FOR TRANSFUSION ACCESSORIES,</i>	
<i>THROUGH 2012 (\$ MILLIONS)</i>	135
TECHNOLOGY	136
CLASSICAL FRACTIONATION METHODS	136
COHN FRACTIONATION.....	136
ADVANCED FRACTIONATION METHODS	136
AMPLIFICATION METHODS.....	137
POLYMERASE CHAIN REACTION (PCR)	137
NUCLEIC AMPLIFICATION TECHNOLOGY (NAT).....	137
IMMUNOASSAY	137

ENZYME IMMUNOASSAY (EIA).....	137
Basic EIA	138
<i>FIGURE 12 THE BASIC ENZYME IMMUNOASSAY (EIA) PROCESS.....</i>	<i>138</i>
Alternate EIA Methods	139
Second Antibody Precipitation Method.....	139
Double Antibody Sandwich Method.....	139
Reverse Sandwich Method	139
Reverse Sandwich Inhibition Method.....	139
Reverse Sandwich ... (Continued)	140
BLOOD INDUSTRY: INTERNATIONAL ANALYSIS	141
GLOBAL MARKETS FOR WHOLE BLOOD COLLECTIONS.....	141
LOCAL EFFORTS AND IMPROVEMENTS	141
South America	141
Asia.....	142
Cuba	142
India	142
Pacific Region.....	143
Australia.....	143
New Zealand	143
Africa	143
South Africa	144
Canada	144
Europe.....	145
Austria.....	145
Britain	145
France.....	145
Germany.....	146
Italy	146
Switzerland	146
Turkey	147
Russia.....	147
GLOBAL MARKETS FOR SOURCE PLASMA COLLECTIONS.....	147
<i>TABLE 58 PROJECTED GLOBAL (U.S. AND OTHER MARKETS)</i>	
<i>PLASMA COLLECTIONS, THROUGH 2012 (\$ BILLIONS,</i>	
<i>MILLIONS LITERS)</i>	<i>148</i>
GLOBAL MARKETS FOR BLOOD THERAPEUTICS.....	148
<i>TABLE 59 PROJECTED WORLD (U.S. AND OTHER MARKETS)</i>	
<i>SALES OF PLASMA PRODUCTS*, THROUGH 2012 (\$ BILLIONS).....</i>	<i>148</i>
GLOBAL MARKETS FOR BLOOD TYPING AND SCREENING	
PRODUCTS	148
<i>TABLE 60 PROJECTED GLOBAL (U.S. AND OTHER) MARKETS FOR</i>	
<i>BLOOD TYPING AND SCREENING PRODUCTS, THROUGH 2012</i>	
<i>(\$ MILLIONS).....</i>	<i>149</i>

GLOBAL MARKETS FOR BLOOD PROCESSING EQUIPMENT AND ASSOCIATED PRODUCTS	149
<i>TABLE 61 PROJECTED WORLD SALES OF BLOOD COLLECTION AND PROCESSING EQUIPMENT AND CONSUMABLES, THROUGH 2012 (\$ MILLIONS)</i>	<i>150</i>
BLOOD RESEARCH AND DEVELOPMENT.....	151
DEDICATED BLOOD RESEARCH FACILITIES	151
JEROME H. HOLLAND LABORATORY (ARC)	151
NATIONAL BLOOD FOUNDATION (NBF)	151
CENTER FOR BLOOD RESEARCH (CBR)	151
Center for Blood Research (CBR)...(Continued)	152
Center for Blood Research (CBR)...(Continued)	153
Center for Blood Research (CBR)...(Continued)	154
<i>TABLE 62 SELECTED ADVANCES IN ADULT STEM CELL THERAPIES</i>	<i>155</i>
<i>TABLE 62 (CONTINUED)</i>	<i>156</i>
BLOOD SUBSTITUTES.....	156
BLOOD SUBSTITUTES (CONTINUED)	156
FIBRIN SEALANT	157
THE VETERINARY BLOOD MARKET	158
<i>TABLE 63 REGIONAL VETERINARY BLOOD BANKS</i>	<i>158</i>
THE VETERINARY BLOOD MARKET (CONTINUED).....	159
COMPANY PROFILES	160
ABBOTT LABORATORIES.....	160
AMERICA'S BLOOD CENTERS.....	160
AMERICAN ASSOCIATION OF BLOOD BANKS (AABB).....	161
AMERICAN RED CROSS (ARC)	161
BAXTER INTERNATIONAL, INC.	162
BIO-RAD LABORATORIES	163
CSL BEHRING	164
GRIFOLS BIOLOGICALS, INC.....	164
GRIFOLS BIOLOGICALS, INC. (CONTINUED)	165
HAEMONETICS, INC.	166
IMMUCOR	167
MASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABS	168
MEDIMMUNE CORPORATION	168
ORTHO-CLINICAL DIAGNOSTICS	169
OLYMPUS DIAGNOSTIC SYSTEMS	170
TALECRIS BIOTHERAPEUTICS	170
PATENT ANALYSIS	171
<i>TABLE 64 RECENTLY ISSUED PATENTS</i>	<i>171</i>
<i>TABLE 65 PATENTS BY COMPANY ASSIGNEE</i>	<i>172</i>

TABLE 65 (CONTINUED)..... 173

APPENDIX	174
PATENTS	174
BLOOD TRANSFUSIONS—11 PATENTS	174
Blood Transfusions—11 Patents /Continued)	175
Blood Transfusions—11 Patents /Continued)	176
Blood Transfusions—11 Patents /Continued)	177
Blood Transfusions—11 Patents /Continued)	178
BLOOD DERIVATIVES—(SEPTEMBER 1986 TO PRESENT)—	
SEVEN PATENTS	179
Blood Derivatives...(Continued)	180
Blood Derivatives...(Continued)	181
Blood Derivatives...(Continued)	182
NUCLEIC ACID AMPLIFICATION (MARCH 2000 TO	
PRESENT) — 40 PATENTS	183
Nucleic Acid Amplification...(Continued).....	184
Nucleic Acid Amplification...(Continued).....	185
Nucleic Acid Amplification...(Continued).....	186
Nucleic Acid Amplification...(Continued).....	187
Nucleic Acid Amplification...(Continued).....	188
Nucleic Acid Amplification...(Continued).....	189
Nucleic Acid Amplification...(Continued).....	190
Nucleic Acid Amplification...(Continued).....	191
Nucleic Acid Amplification...(Continued).....	192
Nucleic Acid Amplification...(Continued).....	193
Nucleic Acid Amplification...(Continued).....	194
Nucleic Acid Amplification...(Continued).....	195
Nucleic Acid Amplification...(Continued).....	196
Nucleic Acid Amplification...(Continued).....	197
Nucleic Acid Amplification...(Continued).....	198
Nucleic Acid Amplification...(Continued).....	199
Nucleic Acid Amplification...(Continued).....	200
Nucleic Acid Amplification...(Continued).....	201
Nucleic Acid Amplification...(Continued).....	202
Nucleic Acid Amplification...(Continued).....	203
Nucleic Acid Amplification...(Continued).....	204
FDA-LICENSED SOURCE PLASMA FACILITIES	205
FDA-LICENSED SOURCE PLASMA ... (CONTINUED).....	206
FDA-LICENSED SOURCE PLASMA ... (CONTINUED).....	207
FDA-LICENSED SOURCE PLASMA ... (CONTINUED).....	208
FDA-LICENSED SOURCE PLASMA ... (CONTINUED).....	209
FDA-LICENSED SOURCE PLASMA ... (CONTINUED).....	210
FDA-LICENSED SOURCE PLASMA ... (CONTINUED).....	211
FDA-LICENSED SOURCE PLASMA ... (CONTINUED).....	212

FDA-LICENSED SOURCE PLASMA ...(CONTINUED).....	213
FDA-LICENSED SOURCE PLASMA ...(CONTINUED).....	214
FDA-LICENSED SOURCE PLASMA ...(CONTINUED).....	215
FDA-LICENSED SOURCE PLASMA ...(CONTINUED).....	216
FDA-LICENSED SOURCE PLASMA ...(CONTINUED).....	217
FDA-LICENSED SOURCE PLASMA ...(CONTINUED).....	218
FDA-LICENSED SOURCE PLASMA ...(CONTINUED).....	219
FDA-LICENSED SOURCE PLASMA ...(CONTINUED).....	220
FDA-LICENSED SOURCE PLASMA ...(CONTINUED).....	221
FDA-LICENSED SOURCE PLASMA ...(CONTINUED).....	222
GUIDANCE FOR INDUSTRY RECOGNITION AND USE OF A STANDARD FOR THE UNIFORM LABELING OF BLOOD AND BLOOD COMPONENTS.....	222
INTRODUCTION.....	222
BACKGROUND	222
FDA REVIEW AND CONCLUSIONS.....	223
REPORTING REQUIREMENTS FOR LICENSED ESTABLISHMENTS	224
SUMMARY	224